Journal
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
Volume 145, Issue 4, Pages 797-810Publisher
SPRINGER
DOI: 10.1007/s00432-019-02882-7
Keywords
Aptamer; Antibody; Cancer cell heterogeneity and plasticity; Targeted therapy; Immunotherapy; SELEX
Categories
Funding
- National Natural Science Foundation of China [81673521, 81872942]
- National Science and Technology Major Project [2018ZX10302-206]
- Key Project of Traditional Chinese Medicine Science and Technology of Zhejiang Province [2015ZZ006]
Ask authors/readers for more resources
PurposeAptamers are a class of single-stranded nucleic acid (DNA or RNA) oligonucleotides that are screened in vitro by a technique called systematic evolution of ligands by exponential enrichment (SELEX). They have stable three-dimensional structures that can bind to various targets with high affinity and specificity. Due to distinct properties such as easy synthesis, high stability, small size, low toxicity and immunogenicity, they have been largely studied as anticancer agents/tools. Consequently, aptamers are starting to play important roles in disease prevention, diagnosis and therapy. This review focuses on studies that evaluated the effect of aptamers on various aspects of cancer therapy. It also provides novel and unique insights into the role of aptamers on the fight against cancer.MethodsWe reviewed literatures about the role of aptamers against cancer from PUBMED databases in this article.ResultsHere, we summarized the role of aptamers on the fight against cancer in a unique point of view. Meanwhile, we presented novel ideas such as aptamer-pool-drug conjugates for the treatment of refractory cancers.ConclusionsAptamers and antibodies should form a coalition against cancers to maximize their advantages and minimize disadvantages.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available